Takeda Pharmaceutical Company Limited (TAK) News

Takeda Pharmaceutical Company Limited (TAK): $13.59

0.54 (+4.14%)

POWR Rating

Component Grades













Filter TAK News Items

TAK News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

TAK News Highlights

  • TAK's 30 day story count now stands at 13.
  • Over the past 24 days, the trend for TAK's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
  • The most mentioned tickers in articles about TAK are TSE, RARE and PBYI.

Latest TAK News From Around the Web

Below are the latest news stories about TAKEDA PHARMACEUTICAL CO LTD that investors may wish to consider to help them evaluate TAK as an investment opportunity.

Strengthening Healthcare Systems to Meet Patients’ Need for Plasma-Derived Therapies

OSAKA, Japan, & GENEVA, Switzerland, September 29, 2022--As part of their well-established partnership, the United Nations Institute for Training and Research (UNITAR) and Takeda (TSE:4502/NYSE:TAK), a global pharmaceutical leader and an active member of the United Nations Global Compact, are pleased to announce a new joint initiative focused on strengthening countries’ healthcare systems to meet patients’ need for plasma and plasma-derived therapies. The initiative will draw on UNITAR’s experti

Yahoo | September 29, 2022

TAK vs. ZTS: Which Stock Should Value Investors Buy Now?

TAK vs. ZTS: Which Stock Is the Better Value Option?

Yahoo | September 21, 2022

Puma Biotech (PBYI) Inks Agreement for Takeda's Alisertib

Puma Biotechnology (PBYI) inks license agreement with Japan's Takeda Pharmaceuticals, gaining worldwide development and commercialization rights to the latter's cancer treatment alisertib.

Yahoo | September 21, 2022

Puma Biotech In-Licenses Takeda's Cancer Candidate With Primary Focus On Breast & Lung Cancer

Puma Biotechnology Inc (NASDAQ: PBYI) announced an agreement with Takeda Pharmaceutical Co Ltd (NYSE: TAK) to license the worldwide research and development and commercial rights to alisertib for cancer indications. Alisertib has been tested in metastatic cancers, including breast cancer, small cell lung cancer, head and neck cancer, ovarian cancer, peripheral T cell lymphoma, and acute myeloid leukemia. Under the terms of the agreement, Puma will assume sole responsibility for the global develo

Yahoo | September 21, 2022

Health Canada approves Takeda's LIVTENCITY™ (maribavir) the First and Only Treatment for Adults with Post-Transplant Cytomegalovirus (CMV) infection

Takeda Canada Inc. ("Takeda") is pleased to announce that Health Canada has authorized (Notice of Compliance) LIVTENCITY™ (maribavir) for the treatment of adults with post-transplant cytomegalovirus (CMV) infection/disease who are refractory (with or without genotypic resistance) to one or more prior antiviral therapies.1 Compared to conventionally used antivirals to treat post-transplant CMV, LIVTENCITY offers twice the efficacy1 and more than 10 times less toxicity.1*

Yahoo | September 20, 2022

Takeda Signs Virtual Power Purchase Agreement with Enel North America to Advance Renewable Energy Production in the United States

OSAKA, Japan & CAMBRIDGE, Mass., September 19, 2022--Takeda (TSE:4502/NYSE:TAK) and Enel North America today announced the signing of a long-term virtual power purchase agreement (VPPA) for the electricity delivered to the power grid from a 79 megawatt (MW) portion of Enel’s Seven Cowboy wind project in the state of Oklahoma in the U.S. The agreement, advised by Edison Energy LLC, advances progress towards achieving Takeda’s goals of reducing 40 percent of scopes 1 and 2 greenhouse gas (GHG) emi

Yahoo | September 19, 2022

Takeda Receives Positive CHMP Opinion for Maribavir for the Treatment of Adults with Post-transplant Cytomegalovirus (CMV) Refractory (With or Without Resistance) to Prior Therapies

OSAKA, Japan & CAMBRIDGE, Mass., September 16, 2022--Takeda (TSE:4502/NYSE:TAK) today announced the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of maribavir for the treatment of cytomegalovirus (CMV) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a hematopoietic stem c

Yahoo | September 16, 2022

Is Takeda Pharmaceutical Co. (TAK) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Yahoo | September 15, 2022

Got $5,000? These 2 Dividend Stocks Haven't Been This Cheap in Years

When dividend stocks dip in price and go on sale, they can create buying opportunities for long-term investors. Takeda Pharmaceuticals (NYSE: TAK) and Verizon Communications (NYSE: VZ) are both at multi-year lows, and here's why they could be attractive options for a $5,000 investment. Takeda Pharmaceuticals is one of the largest drug companies in the world.

Yahoo | September 14, 2022

Takeda Launches CDPATH™, a Personalized Prognostic Tool, Advancing Innovation for Patients with Crohn's Disease

Takeda (TSE:4502/NYSE:TAK) today announced the national launch of the CDPATH™ program, which includes an innovative, validated personalized prognostic tool that uses blood tests† to help predict the potential risk of developing serious Crohn's disease-related complications within three years.1,2 CDPATH is available for use by US-based physicians and offered at no cost to eligible patients††, providing an opportunity for patients to partner with their physicians to map out a personalized disease

Yahoo | September 14, 2022

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.7799 seconds.